Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - Sunshine Biopharma, Inc | sbfm_ex991.htm |
| EX-10.15 - FINANCING AGREEMENT WITH RB CAPITAL PARTNERS, INC. - Sunshine Biopharma, Inc | sbfm_ex1015.htm |
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Form 8-K
Current
Report Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported):
September 14, 2020
SUNSHINE BIOPHARMA, INC.
(Exact
name of small business issuer as specified in its
charter)
|
Colorado
|
000-52898
|
20-5566275
|
|
(State
or other jurisdiction
of
incorporation)
|
(Commission
File Number)
|
(IRS
Employer ID No.)
|
6500 Trans-Canada Highway
4th Floor
Pointe-Claire, Quebec, Canada H9R 0A5
(Address
of principal executive offices)
514) 426-6161
(Issuer’s
Telephone Number)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
Emerging
growth company [X]
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
[ ]
Item 1.01 Entry into a Material Definitive Agreement
On
September 8, 2020, we executed a Financing Agreement with RB
Capital Partners, Inc., La Jolla, CA, who has agreed to provide us
with a minimum of $2 million in convertible debt financing over the
next three to six months pursuant to the terms and conditions
included in relevant Promissory Notes (the “Promissory
Notes”). On September 14, 2020, we received notice of the
initial $250,000 funding under this agreement.
The
Promissory Notes will bear interest at the rate of 5% per annum and
will be fully convertible into shares of our Common Stock at a
conversion price equal to the market value of our Common Stock on
the applicable conversion date or $0.30 per share, whichever is
greater. The Promissory Notes will have a maturity date of two
years from the date of issuance and must be fully converted on or
before the maturity date. We have the right under these Promissory
Notes to pay off all or any part of the Promissory Notes at any
time without penalty.
We
intend to use the proceeds for development of our recently
announced Coronavirus treatment on a priority basis and the
clinical development of Adva-27a, our flagship anticancer compound
targeted for pancreatic cancer.
Item 7.01 Regulation FD Disclosure
Attached
is a copy of a press release being issued by us relating to the
agreement with RB Capital Partners, Inc., a copy of which is
attached as Exhibit 99.1 and is hereby incorporated.
Item 9.01 Financial Statements and Exhibits
(b)
Exhibits. The following exhibits are included in this
report:
| No. | Description |
| 10.15 | Financing Agreement with RB Capital Partners, Inc. |
|
Press Release
announcing the Financing Agreement
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
SUNSHINE
BIOPHARMA, INC.
(Registrant)
|
|
|
|
|
|
|
|
|
Dated: September
15, 2020
|
By:
|
/s/ Dr. Steve N.
Slilaty
|
|
|
|
|
Dr. Steve N.
Slilaty, Chief Executive Officer
|
|
|
|
|
|
|